Wassenaar arrangement [ COCOM | Coordinating Committee for Multilateral Export Controls | Wassenaar Arrangement on Export Controls for Conventional Arms and Dual-Use Goods and Technologies ]

users committee | user's committee | resident committee | beneficiaries committee

Committee for Medicinal Products for Human Use | Committee for Proprietary Medicinal Products | CHMP [Abbr.] | CPMP [Abbr.]

user-user protocol

Standing Committee on Medical Products for Veterinary Use

examination table sheeting

daily shampoo | everyday shampoo

user name | username | user identifier | user ID | login name | logon name | login ID | logon ID | user identification code | personal identifier | connection login

drug addiction [ drug abuse | drug-taking | fight against drugs | drug addicts(UNBIS) ]

In order to ensure harmonised responses across the Union to safety concerns regarding medicinal products for human use, the Committee for Medicinal Products for Human Use and the coordination group established by Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use should rely on the recommendations of the Pharmacovigilance Risk Assessment Committee with regard to any question relating to the pharmacovigilance of medicinal products for human use.

Where this opinion of the Committee for Medicinal Products for Human Use differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, the Committee for Medicinal Products for Human Use shall attach to its opinion a detailed explanation of the scientific grounds for the differences together with the recommendation.

Where the opinion of the Committee on Medicinal Products for Human Use differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, the Committee on Medicinal Products for Human Use shall attach to its opinion a detailed explanation of the scientific grounds for the differences, together with the recommendation.

In order to ensure harmonised responses across the Union to safety concerns regarding medicinal products for human use, the Committee for Medicinal Products for Human Use and the coordination group established by Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (6) should rely on the recommendations of the Pharmacovigilance Risk Assessment Committee with regard to any question relating to the pharmacovigilance of medicinal products for human use.